Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pseudostat Cortecs Ltd.

T Jones1

  • 1Head of Formulation, Centre for Applied Microbiology and Research, Experimental Vaccines Section, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. taff.jones@camr.org.uk

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conducting a systematic review.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2001
Same author

Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

The use of particle beam mass spectrometry for the measurement of impurities in a nabumetone drug substance, not easily amenable to atmospheric pressure ionisation techniques.

Rapid communications in mass spectrometry : RCM·2001
Same author

Effect of chlorsulfuron on growth of submerged aquatic macrophyte Potamogeton pectinatus (sago pondweed).

Environmental pollution (Barking, Essex : 1987)·2001
Same author

Infrequent genetic exchange and recombination in the mitochondrial genome of Candida albicans.

Journal of bacteriology·2001
Same author

Molecular characterization of a cDNA encoding functional human CLK4 kinase and localization to chromosome 5q35 [correction of 4q35].

Genomics·2001
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Pseudostat, an oral vaccine for Pseudomonas aeruginosa, significantly reduced acute infective episodes in patients with chronic bronchitis. This oral vaccine shows promise for treating lung infections in respiratory disorders like cystic fibrosis.

Area of Science:

  • Respiratory Medicine
  • Vaccinology
  • Infectious Diseases

Background:

  • Pseudomonas aeruginosa and Haemophilus influenza are common pathogens in respiratory disorders.
  • Chronic lung infections pose significant challenges in conditions like cystic fibrosis, bronchitis, and bronchiectasis.
  • Current treatments for these infections have limitations, driving the need for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of Pseudostat, an oral vaccine derived from Pseudomonas aeruginosa.
  • To assess Pseudostat's potential in the treatment and prophylaxis of lung infections caused by P aeruginosa and H influenza.
  • To investigate Pseudostat's impact on acute infective episodes and disease severity in patients with chronic respiratory conditions.

Main Methods:

Related Experiment Videos

  • Phase II and Phase I/II clinical trials were conducted in patients with chronic bronchitis, cystic fibrosis, and bronchiectasis.
  • Participants received oral Pseudostat or placebo.
  • Efficacy was assessed by monitoring acute infective episodes, hospital days, and sputum white blood cell content.

Main Results:

  • Pseudostat treatment led to a 10-fold reduction in acute infective episodes compared to placebo in chronic bronchitis patients.
  • In one study, Pseudostat reduced acute infection episodes by 90% and resulted in zero hospital days for the treated group.
  • A reduction in sputum white blood cell content was observed in bronchiectasis patients, indicating decreased infection severity.

Conclusions:

  • Pseudostat demonstrates significant potential as an oral vaccine for preventing and treating lung infections in patients with chronic respiratory diseases.
  • The vaccine appears well-tolerated, with no adverse or toxic effects reported in Phase I trials.
  • Further clinical development, including Phase III trials, is warranted to confirm Pseudostat's efficacy and safety profile.